HK1020875A1 - Tablet with controlled release of alfuzosine chlorydrate - Google Patents

Tablet with controlled release of alfuzosine chlorydrate

Info

Publication number
HK1020875A1
HK1020875A1 HK99105968A HK99105968A HK1020875A1 HK 1020875 A1 HK1020875 A1 HK 1020875A1 HK 99105968 A HK99105968 A HK 99105968A HK 99105968 A HK99105968 A HK 99105968A HK 1020875 A1 HK1020875 A1 HK 1020875A1
Authority
HK
Hong Kong
Prior art keywords
alfuzosine
chlorydrate
tablet
controlled release
release
Prior art date
Application number
HK99105968A
Other languages
English (en)
Inventor
Lauretta Maggi
Ubaldo Conte
Pascal Grenier
Guy Vergnault
Alain Dufour
Francois Xavier Jarreau
Clemence Rauch-Desanti
Original Assignee
Sanofi Synthelabo
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1020875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr
Application filed by Sanofi Synthelabo, Jagotec Ag filed Critical Sanofi Synthelabo
Publication of HK1020875A1 publication Critical patent/HK1020875A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK99105968A 1996-08-29 1999-12-20 Tablet with controlled release of alfuzosine chlorydrate HK1020875A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9610551A FR2752737B1 (fr) 1996-08-29 1996-08-29 Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386 1997-04-10
PCT/FR1997/001515 WO1998008515A1 (fr) 1996-08-29 1997-08-22 Comprime a liberation controlee de chlorhydrate d'alfuzosine

Publications (1)

Publication Number Publication Date
HK1020875A1 true HK1020875A1 (en) 2000-05-26

Family

ID=26232935

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99105968A HK1020875A1 (en) 1996-08-29 1999-12-20 Tablet with controlled release of alfuzosine chlorydrate

Country Status (37)

Country Link
US (1) US6149940A (bg)
EP (1) EP0938318B1 (bg)
JP (1) JP3797388B2 (bg)
KR (1) KR100364328B1 (bg)
CN (2) CN1155382C (bg)
AP (1) AP1107A (bg)
AR (1) AR009312A1 (bg)
AT (1) ATE200864T1 (bg)
AU (1) AU724490B2 (bg)
BG (1) BG63768B1 (bg)
BR (1) BR9713237B1 (bg)
CA (1) CA2264250C (bg)
CO (1) CO4920217A1 (bg)
CY (1) CY2284B1 (bg)
CZ (1) CZ295066B6 (bg)
DE (1) DE69704712T2 (bg)
DK (1) DK0938318T3 (bg)
EE (1) EE03855B1 (bg)
ES (1) ES2159400T3 (bg)
GR (1) GR3036291T3 (bg)
HK (1) HK1020875A1 (bg)
HU (1) HU228007B1 (bg)
IL (1) IL128146A (bg)
IS (1) IS2091B (bg)
MX (1) MXPA99001958A (bg)
NO (1) NO326206B1 (bg)
NZ (1) NZ334018A (bg)
OA (1) OA10983A (bg)
PL (1) PL191546B1 (bg)
PT (1) PT938318E (bg)
RU (1) RU2183459C2 (bg)
SI (1) SI0938318T1 (bg)
SK (1) SK284388B6 (bg)
TR (1) TR199900289T2 (bg)
TW (1) TW522023B (bg)
UA (1) UA69374C2 (bg)
WO (1) WO1998008515A1 (bg)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114209668A (zh) * 2022-01-13 2022-03-22 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720471B1 (en) 1998-04-28 2004-04-13 The Procter & Gamble Company Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
AU767812B2 (en) 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
AR030557A1 (es) 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) * 2001-02-08 2005-12-23 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) * 2001-02-08 2003-12-05 Ellipse Pharmaceuticals Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US6852238B2 (en) * 2002-08-29 2005-02-08 Steller Technology Company Layered tablet water treatment compositions and method of use
US7309444B2 (en) * 2002-08-29 2007-12-18 Stellar Technology Company Layered tablet water treatment compositions and method of use
ES2677769T3 (es) 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Subunidad secuestrante y composiciones y procedimientos relacionados
WO2004037228A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Sustained release compositions containing alfuzosin
JP2008508227A (ja) * 2004-07-29 2008-03-21 サノフイ−アベンテイス 高ｐｈ依存性溶解度を有する有効成分の放出制御のための医薬品多層錠剤
FR2874325B1 (fr) * 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062846A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
US20060062845A1 (en) * 2004-09-17 2006-03-23 Cimex Pharma Ag Alfuzosin tablets and synthesis
ITMI20050391A1 (it) * 2005-03-11 2006-09-12 Ph & T S P A Formulazioni a rilascio controllato di alfuzosin
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
CA2607004C (en) 2005-05-05 2016-01-26 Sensient Flavors Inc. Production of beta-glucans and mannans
US20070185233A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20070185236A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070185235A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive compositions
US20070129460A1 (en) * 2005-11-09 2007-06-07 Jayanth Rajaiah Denture adhesive articles
US20070185232A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
US20090238776A1 (en) * 2005-11-09 2009-09-24 Arif Ali Baig Oral Care Compositions and Methods
US7834066B2 (en) * 2005-11-09 2010-11-16 The Procter & Gamble Company Denture adhesive articles
US20070185237A1 (en) * 2005-11-09 2007-08-09 Jayanth Rajaiah Denture adhesive articles
EP1976488A4 (en) * 2006-01-12 2010-02-10 Wockhardt Ltd ALFUZOSIN PROLONGED RELEASE PREPARATIONS
KR20140018439A (ko) 2006-05-02 2014-02-12 프로테우스 디지털 헬스, 인코포레이티드 환자 주문형 치료법
ES2385612T3 (es) 2006-06-19 2012-07-27 Alpharma Pharmaceuticals, Llc Composiciones farmacéuticas
US20080003286A1 (en) * 2006-06-29 2008-01-03 Sathya Narayana Vemula Sustained delivery alfuzosin compositions
CA2664641A1 (en) 2006-09-26 2008-04-10 Astellas Pharma, Inc. Controlled release dosage form of tacrolimus
US20080095844A1 (en) * 2006-10-23 2008-04-24 Rajhans Sujay Kamalakar Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
KR101611240B1 (ko) 2006-10-25 2016-04-11 프로테우스 디지털 헬스, 인코포레이티드 복용 가능한 제어된 활성화 식별자
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
US20080138412A1 (en) * 2006-12-06 2008-06-12 Fu-Yung Lin Sustained release alfuzosin hydrochl formulation and method for their production
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
WO2008073388A2 (en) * 2006-12-11 2008-06-19 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making and methods of use
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
CN101686800A (zh) 2007-02-01 2010-03-31 普罗秋斯生物医学公司 可摄入事件标记器系统
AU2008216170B2 (en) 2007-02-14 2012-07-26 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CN102014867A (zh) 2008-03-05 2011-04-13 普罗秋斯生物医学公司 多模式通信可摄取事件标记和系统，及使用其的方法
MX2010013342A (es) * 2008-06-04 2010-12-21 Procter & Gamble Composiciones adhesivas para dentaduras postizas y metodos de elaboracion.
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
CA2734251A1 (en) 2008-08-13 2010-02-18 Proteus Biomedical, Inc. Ingestible circuitry
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
KR20110103446A (ko) 2009-01-06 2011-09-20 프로테우스 바이오메디컬, 인코포레이티드 섭취-관련 바이오피드백 및 개별화된 의료 치료 방법 및 시스템
WO2010080764A2 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. Pharmaceutical dosages delivery system
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
WO2010111403A2 (en) 2009-03-25 2010-09-30 Proteus Biomedical, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
EP2424427B1 (en) 2009-04-28 2021-06-16 Otsuka Pharmaceutical Co., Ltd. Highly reliable ingestible event markers
WO2010132331A2 (en) 2009-05-12 2010-11-18 Proteus Biomedical, Inc. Ingestible event markers comprising an ingestible component
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
CN107411973A (zh) 2010-03-10 2017-12-01 宝洁公司 义齿粘合剂组合物
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
CN102905672B (zh) 2010-04-07 2016-08-17 普罗秋斯数字健康公司 微型可吞服装置
JP5905872B2 (ja) * 2010-04-07 2016-04-20 ルピン・リミテッド タペンタドールの制御放出医薬組成物
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
CN102475690B (zh) * 2010-11-30 2016-06-01 安国药品株式会社 内含盐酸阿夫唑嗪的缓释片剂
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
CA2842952C (en) 2011-07-21 2019-01-08 Proteus Digital Health, Inc. Mobile communication device, system, and method
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
KR20150038038A (ko) 2012-07-23 2015-04-08 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 부품을 포함하는 섭취 가능한 이벤트 마커를 제조하기 위한 기술
BR112015008434A2 (pt) 2012-10-18 2017-07-04 Proteus Digital Health Inc aparelho, sistema e método para otimizar adaptativamente a dissipação de potência e a potência de radiodifusão em uma fonte de alimentação para um dispositivo de comunicação
WO2014120669A1 (en) * 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Highly-swellable polymeric films and compositions comprising the same
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
EP3005281A4 (en) 2013-06-04 2017-06-28 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) * 2015-11-05 2017-05-11 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
EP3487393A4 (en) 2016-07-22 2020-01-15 Proteus Digital Health, Inc. ELECTROMAGNETIC CAPTURE AND DETECTION OF INGERABLE EVENT MARKERS
TWI735689B (zh) 2016-10-26 2021-08-11 日商大塚製藥股份有限公司 製造含有可攝食性事件標記之膠囊之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) * 1993-05-29 1993-07-14 Danbiosyst Uk Controlled release drug formulation
FR2717388B1 (fr) * 1994-03-21 1996-11-22 Synthelabo Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114209668A (zh) * 2022-01-13 2022-03-22 山东新时代药业有限公司 一种盐酸阿夫唑嗪缓释制剂及其制备方法

Also Published As

Publication number Publication date
KR100364328B1 (ko) 2002-12-26
CO4920217A1 (es) 2000-05-29
NO326206B1 (no) 2008-10-20
SK284388B6 (sk) 2005-02-04
IL128146A (en) 2001-01-11
DK0938318T3 (da) 2001-08-20
CY2284B1 (en) 2003-07-04
WO1998008515A1 (fr) 1998-03-05
NZ334018A (en) 1999-06-29
AP1107A (en) 2002-09-20
CN100335057C (zh) 2007-09-05
IS2091B (is) 2006-03-15
CA2264250C (en) 2005-07-05
HUP9903428A2 (hu) 2000-02-28
AP9901470A0 (en) 1999-03-31
UA69374C2 (uk) 2004-09-15
NO990944L (no) 1999-04-27
US6149940A (en) 2000-11-21
TR199900289T2 (xx) 2000-12-21
DE69704712T2 (de) 2001-11-29
GR3036291T3 (en) 2001-10-31
EP0938318A1 (fr) 1999-09-01
PL331862A1 (en) 1999-08-16
CA2264250A1 (en) 1998-03-05
ATE200864T1 (de) 2001-05-15
PL191546B1 (pl) 2006-06-30
OA10983A (fr) 2003-03-04
IL128146A0 (en) 1999-11-30
MXPA99001958A (es) 2005-09-08
SK27099A3 (en) 1999-12-10
RU2183459C2 (ru) 2002-06-20
CN1543954A (zh) 2004-11-10
AU724490B2 (en) 2000-09-21
PT938318E (pt) 2001-10-30
BR9713237B1 (pt) 2009-01-13
HUP9903428A3 (en) 2000-04-28
JP2000514462A (ja) 2000-10-31
KR20000035929A (ko) 2000-06-26
BG63768B1 (bg) 2002-12-29
BR9713237A (pt) 2000-04-04
SI0938318T1 (en) 2001-12-31
AU4020197A (en) 1998-03-19
JP3797388B2 (ja) 2006-07-19
EP0938318B1 (fr) 2001-05-02
EE03855B1 (et) 2002-10-15
HU228007B1 (en) 2012-08-28
EE9900090A (et) 1999-10-15
BG103138A (bg) 1999-09-30
CZ295066B6 (cs) 2005-05-18
AR009312A1 (es) 2000-04-12
ES2159400T3 (es) 2001-10-01
NO990944D0 (no) 1999-02-26
IS4964A (is) 1999-01-29
CN1155382C (zh) 2004-06-30
DE69704712D1 (de) 2001-06-07
CZ65599A3 (cs) 1999-06-16
TW522023B (en) 2003-03-01
CN1228700A (zh) 1999-09-15

Similar Documents

Publication Publication Date Title
AP9901470A0 (en) Tablet with controlled release of alfuzosine chlorydrate
AU3406497A (en) Controlled release tablet
EP1019100A4 (en) PROLONGED RELEASE OF SUBSTANCES
IL119660A0 (en) Controlled release formulation
AU5171196A (en) Controlled release tablet
GB9413957D0 (en) Release devices
GB9519094D0 (en) Granulated active with controlled release
AU132520S (en) Tablet
ZA959221B (en) Cisapride extended release
IL118932A0 (en) Controlled release tablets
AU133610S (en) Tablet
GB9507139D0 (en) Release units
GB9600390D0 (en) Preparation of tablets
EP0906754A4 (en) S1452 QUICK RELEASE TABLETS
ZA977766B (en) Tablet with controlled release of alfuzosin hydrochloride.
IL117677A0 (en) Controlled release tablets
GB9320733D0 (en) Controlled release device construction
GB9404544D0 (en) Controlled release formulation
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
GB9411652D0 (en) Controlled release granules
CA80217S (en) Tablet
CA80450S (en) Tablet
CA80449S (en) Tablet
HUP9602759A3 (en) Antiseptic tablet
GB9604809D0 (en) Ornamental object

Legal Events

Date Code Title Description
PF Patent in force
CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20170821